Precision medicine in pediatric oncology: Translating genomic discoveries into optimized therapies

Thai Hoa Tran, Avanthi Tayi Shah, Mignon L. Loh

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Survival of children with cancers has dramatically improved over the past several decades. This success has been achieved through improvement of combined modalities in treatment approaches, intensification of cytotoxic chemotherapy for those with high-risk disease, and refinement of risk stratification incorporating novel biologic markers in addition to traditional clinical and histologic features. Advances in cancer genomics have shed important mechanistic insights on disease biology and have identified "driver" genomic alterations, aberrant activation of signaling pathways, and epigenetic modifiers that can be targeted by novel agents. Thus, the recently described genomic and epigenetic landscapes of many childhood cancers have expanded the paradigm of precision medicine in the hopes of improving outcomes while minimizing toxicities. In this review, we will discuss the biologic rationale for molecularly targeted therapies in genomically defined subsets of pediatric leukemias, solid tumors, and brain tumors.

Original languageEnglish (US)
Pages (from-to)5329-5338
Number of pages10
JournalClinical Cancer Research
Volume23
Issue number18
DOIs
StatePublished - Sep 15 2017

Fingerprint

Precision Medicine
Pediatrics
Epigenomics
Neoplasms
Therapeutics
Genomics
Brain Neoplasms
Leukemia
Biomarkers
Drug Therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Precision medicine in pediatric oncology : Translating genomic discoveries into optimized therapies. / Tran, Thai Hoa; Shah, Avanthi Tayi; Loh, Mignon L.

In: Clinical Cancer Research, Vol. 23, No. 18, 15.09.2017, p. 5329-5338.

Research output: Contribution to journalReview article

Tran, Thai Hoa ; Shah, Avanthi Tayi ; Loh, Mignon L. / Precision medicine in pediatric oncology : Translating genomic discoveries into optimized therapies. In: Clinical Cancer Research. 2017 ; Vol. 23, No. 18. pp. 5329-5338.
@article{07df92936bde45c2b51f8ec377173350,
title = "Precision medicine in pediatric oncology: Translating genomic discoveries into optimized therapies",
abstract = "Survival of children with cancers has dramatically improved over the past several decades. This success has been achieved through improvement of combined modalities in treatment approaches, intensification of cytotoxic chemotherapy for those with high-risk disease, and refinement of risk stratification incorporating novel biologic markers in addition to traditional clinical and histologic features. Advances in cancer genomics have shed important mechanistic insights on disease biology and have identified {"}driver{"} genomic alterations, aberrant activation of signaling pathways, and epigenetic modifiers that can be targeted by novel agents. Thus, the recently described genomic and epigenetic landscapes of many childhood cancers have expanded the paradigm of precision medicine in the hopes of improving outcomes while minimizing toxicities. In this review, we will discuss the biologic rationale for molecularly targeted therapies in genomically defined subsets of pediatric leukemias, solid tumors, and brain tumors.",
author = "Tran, {Thai Hoa} and Shah, {Avanthi Tayi} and Loh, {Mignon L.}",
year = "2017",
month = "9",
day = "15",
doi = "10.1158/1078-0432.CCR-16-0115",
language = "English (US)",
volume = "23",
pages = "5329--5338",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "18",

}

TY - JOUR

T1 - Precision medicine in pediatric oncology

T2 - Translating genomic discoveries into optimized therapies

AU - Tran, Thai Hoa

AU - Shah, Avanthi Tayi

AU - Loh, Mignon L.

PY - 2017/9/15

Y1 - 2017/9/15

N2 - Survival of children with cancers has dramatically improved over the past several decades. This success has been achieved through improvement of combined modalities in treatment approaches, intensification of cytotoxic chemotherapy for those with high-risk disease, and refinement of risk stratification incorporating novel biologic markers in addition to traditional clinical and histologic features. Advances in cancer genomics have shed important mechanistic insights on disease biology and have identified "driver" genomic alterations, aberrant activation of signaling pathways, and epigenetic modifiers that can be targeted by novel agents. Thus, the recently described genomic and epigenetic landscapes of many childhood cancers have expanded the paradigm of precision medicine in the hopes of improving outcomes while minimizing toxicities. In this review, we will discuss the biologic rationale for molecularly targeted therapies in genomically defined subsets of pediatric leukemias, solid tumors, and brain tumors.

AB - Survival of children with cancers has dramatically improved over the past several decades. This success has been achieved through improvement of combined modalities in treatment approaches, intensification of cytotoxic chemotherapy for those with high-risk disease, and refinement of risk stratification incorporating novel biologic markers in addition to traditional clinical and histologic features. Advances in cancer genomics have shed important mechanistic insights on disease biology and have identified "driver" genomic alterations, aberrant activation of signaling pathways, and epigenetic modifiers that can be targeted by novel agents. Thus, the recently described genomic and epigenetic landscapes of many childhood cancers have expanded the paradigm of precision medicine in the hopes of improving outcomes while minimizing toxicities. In this review, we will discuss the biologic rationale for molecularly targeted therapies in genomically defined subsets of pediatric leukemias, solid tumors, and brain tumors.

UR - http://www.scopus.com/inward/record.url?scp=85029523286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029523286&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-16-0115

DO - 10.1158/1078-0432.CCR-16-0115

M3 - Review article

C2 - 28600472

AN - SCOPUS:85029523286

VL - 23

SP - 5329

EP - 5338

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 18

ER -